Page 321 - Drug Class Review

Drug Effectiveness Review Project

Drugs Authors: Kumar et al. 91 (Subgroup analysis of Corey-Bloom et al.) Evaluate the efficacy and safety of the centrally acting ChE inhibitor RIV tartrate for patients with mild to moderately severe AD with or without concurrent VRF Setting: Multi-center (22) placebo rivastigmine rivastigmine N/A 6-12 mg/d 1-4 mg/d 26 weeks 26 weeks 26 weeks 235 231 233 Age between 45 and 89 years; non-childbearing potential for females; criteria for AD according to DSM- IV; probable AD according to NINCDS/ADRDA criteria; mild-to-moderate impairment based on MMSE score between 10 and

Alzheimer Year: 2000 Country: US Novartis Study design: RCT Sample size: 699

Final Report Update 1 Subgroups STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs